Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers, optionally in combination with growth hormone, to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of KATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are methods of co-administering KATP channel openers with other drugs (e.g., in combination with growth hormone) to treat diseases of humans and animals (e.g., Prader-Willi Syndrome (PWS), Smith-Magenis syndrome (SMS), and the like.

Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers, optionally in combination with growth hormone, to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of KATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are methods of co-administering KATP channel openers with other drugs (e.g., in combination with growth hormone) to treat diseases of humans and animals (e.g., Prader-Willi Syndrome (PWS), Smith-Magenis syndrome (SMS), and the like.

This invention relates to the prophylactic and/or therapeutic application of antimicrobials that are, for example, administered orally as a delayed release formulation designed to release the drug to the distal small intestine and/or colon in high quantities and density, as a method for the prevention and/or treatment of infections in the colon.

This invention relates to the prophylactic and/or therapeutic application of antimicrobials that are, for example, administered orally as a delayed release formulation designed to release the drug to the distal small intestine and/or colon in high quantities and density, as a method for the prevention and/or treatment of infections in the colon.

A method for the prevention or elimination of biofilm microorganisms on at least one surface of a medical device, the method comprising the steps of: (a) providing a biofilm-active composition having at least one biofilm-active agent; and (b) delivering the biofilm-active composition to the medical device in an amount sufficient to prevent or eliminate the biofilm microorganisms on at least one surface of the medical device.

A method for the prevention or elimination of biofilm microorganisms on at least one surface of a medical device, the method comprising the steps of: (a) providing a biofilm-active composition having at least one biofilm-active agent; and (b) delivering the biofilm-active composition to the medical device in an amount sufficient to prevent or eliminate the biofilm microorganisms on at least one surface of the medical device.

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein. ##STR00001##

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein. ##STR00001##

The present invention provides a compound with a general formula (I) ##STR00001##
or a salt thereof, wherein, R.sup.1 and R.sup.2, are, independently of each other, F or C.sub.nF.sub.2n+1 with n=1-10, and R.sup.3 and R.sup.4 are, independently of each other, C.sub.1-C.sub.10-alkyl.

The present invention provides a compound with a general formula (I) ##STR00001##
or a salt thereof, wherein, R.sup.1 and R.sup.2, are, independently of each other, F or C.sub.nF.sub.2n+1 with n=1-10, and R.sup.3 and R.sup.4 are, independently of each other, C.sub.1-C.sub.10-alkyl.